Oculis Holding’s OCS-05 Shows Promising Results in Phase 2 Trial for Acute Optic Neuritis

Oculis Holding ( (OCS) ) has issued an update.

Oculis Holding has announced positive results from a Phase 2 trial for OCS-05, a potential first-in-class neuroprotective therapy for acute optic neuritis. The trial met its primary safety endpoint and showed significant efficacy in improving retinal structure and visual function, highlighting its potential impact on treating neurodegenerative conditions. The company’s advancement with OCS-05, backed by FDA clearance and a solid financial position, marks a significant step in its development pipeline and could have broad implications for neuro-ophthalmic diseases.

More about Oculis Holding

Oculis Holding AG is a global biopharmaceutical company focused on saving sight and improving eye care. It specializes in developing treatments for ophthalmic conditions, with a particular focus on neuroprotective therapies for conditions like acute optic neuritis.

YTD Price Performance: 3.72%

Average Trading Volume: 52,826

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $733M

For detailed information about OCS stock, go to TipRanks’ Stock Analysis page.